A co-delivery system based on paclitaxel grafted mPEG-b-PLG loaded with doxorubicin: Preparation, in vitro and in vivo evaluation

International Journal of Pharmaceutics

Volumn 471, Issue 1-2, 2014, Pages 412-420

  Li, Qian ^a,b   Lv, Shixian ^a,d   Tang, Zhaohui ^a   Liu, Muhua ^b   Zhang, Dawei ^a   Yang, Yan ^c   Chen, Xuesi ^a  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b JIANGXI AGRICULTURAL UNIVERSITY   (China)

^c JILIN UNIVERSITY   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Co delivery; Doxorubicin; Human breast cancer; Paclitaxel; Poly(l glutamic acid)

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; MACROGOL; NANOPARTICLE; PACLITAXEL; POLYGLUTAMIC ACID; DRUG CARRIER; DRUG COMBINATION; MACROGOL DERIVATIVE; METHOXYPOLY(ETHYLENE GLYCOL)-BLOCK-POLY(GLUTAMIC ACID);

ANIMAL MODEL; AQUEOUS SOLUTION; ARTICLE; BLOOD PH; BREAST TUMOR; CANCER CELL LINE; CANCER INHIBITION; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG SCREENING; ENCAPSULATION; ENDOSOME; ESTERIFICATION; FEMALE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STATIC ELECTRICITY; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; MCF 7 CELL LINE; PARTICLE SIZE; SOLUBILITY; SURFACE PROPERTY; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; DRUG COMBINATIONS; DRUG LIBERATION; DRUG SYNERGISM; FEMALE; HUMANS; MCF-7 CELLS; MICE, INBRED BALB C; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLUTAMIC ACID; SOLUBILITY; SURFACE PROPERTIES; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902346219     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.05.065     Document Type: Article

References (46)

1. E. Blanco, A. Hsiao, A.P. Mann, M.G. Landry, F. Meric-Bernstam, and M. Ferrari Nanomedicine in cancer therapy: innovative trends and prospects Cancer Sci. 102 2011 1247 1252
2. T. Boulikas, and M. Vougiouka Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review) Oncol. Rep. 11 2004 559 595
3. F. Chen, D. Dong, Y. Fu, Y. Zheng, S. Liu, M. Chang, and X. Jing Anti-tumor activity of biodegradable polymer-paclitaxel conjugated micelle against mice U14cervical cancers Chem. Res. Chin. Univ. 28 2012 656 661
4. U.-J. Choe, V. Sun, J.-K. Tan, and D. Kamei Self-assembled polypeptide and polypeptide hybrid vesicles: from synthesis to application T. Deming, Peptide-based Materials 2012 Springer Berlin, Heidelberg 117 134
5. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
6. T.J. Deming Synthetic polypeptides for biomedical applications Prog. Polym. Sci. 32 2007 858 875 (Pubitemid 47202019)
7. C. Deng, Y. Jiang, R. Cheng, F. Meng, and Z. Zhong Biodegradable polymeric micelles for targeted and controlled anticancer drug delivery: promises, progress and prospects Nano Today 7 2012 467 480
8. R. Duncan Polymer conjugates as anticancer nanomedicines Nat. Rev. Cancer 6 2006 688 701 (Pubitemid 44286001)
9. J. Gehl, M. Boesgaard, T. Paaske, B.V. Jensen, and P. Dombernowsky Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic Ann. Oncol. 7 1996 687 693 (Pubitemid 26323541)
10. S. Greenberg, and H.S. Rugo Challenging clinical scenarios: treatment of patients with triple-negative or basal-like metastatic breast cancer Clin. Breast Cancer 10 2 2010 S20 S29
11. J. Hrkach, D. Von Hoff, M.M. Ali, E. Andrianova, J. Auer, T. Campbell, D. De Witt, M. Figa, M. Figueiredo, A. Horhota, S. Low, K. McDonnell, E. Peeke, B. Retnarajan, A. Sabnis, E. Schnipper, J.J. Song, Y.H. Song, J. Summa, D. Tompsett, G. Troiano, T. Van Geen Hoven, J. Wright, P. LoRusso, P.W. Kantoff, N.H. Bander, C. Sweeney, O.C. Farokhzad, R. Langer, and S. Zale Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile Sci. Transl. Med. 4 2012 128139
12. Y. Huang, Z. Tang, X. Zhang, H. Yu, H. Sun, X. Pang, and X. Chen pH-triggered charge-reversal polypeptide nanoparticles for cisplatin delivery: preparation and in vitro evaluation Biomacromolecules 14 2013 2023 2032
13. Y. Huang, Z.H. Tang, X.F. Zhang, H.Y. Yu, H. Sun, X. Pang, and X.S. Chen Ph-triggered charge-reversal polypeptide nanoparticles for cisplatin delivery: preparation and in vitro evaluation Biomacromolecules 14 2013 2023 2032
14. N.T. Huynh, C. Passirani, P. Saulnier, and J.P. Benoit Lipid nanocapsules: a new platform for nanomedicine Int. J. Pharm. 379 2009 201 209
15. H.M. Kieler-Ferguson, J.M.J. Fréchet, and F.C. Szoka Jr Clinical developments of chemotherapeutic nanomedicines: polymers and liposomes for delivery of camptothecins and platinum (II) drugs Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5 2013 130 138
16. C.J. Langer, K.J. O'Byrne, M.A. Socinski, S.M. Mikhailov, K. Lesniewski-Kmak, M. Smakal, T.E. Ciuleanu, S.V. Orlov, M. Dediu, and D. Heigener Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer J. Thoracic Oncol. 3 2008 623 630 (Pubitemid 351787307)
17. A.L.Z. Lee, Y. Wang, H.Y. Cheng, S. Pervaiz, and Y.Y. Yang The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles Biomaterials 30 2009 919 927
18. Y. Lei, Y. Lai, Y. Li, S. Li, G. Cheng, D. Li, H. Li, B. He, and Z. Gu Anticancer drug delivery of PEG based micelles with small lipophilic moieties Int. J. Pharm. 453 2013 579 586
19. D. Li, J.X. Ding, Z.H. Tang, H. Sun, X.L. Zhuang, J.Z. Xu, and X.S. Chen In vitro evaluation of anticancer nanomedicines based on doxorubicin and amphiphilic Y-shaped copolymers Int. J. Nanomed. 7 2012 2687 2697
20. M. Li, S. Lv, Z. Tang, W. Song, H. Yu, H. Sun, H. Liu, and X. Chen Polypeptide/doxorubicin hydrochloride polymersomes prepared through organic solvent-free technique as a smart drug delivery platform Macromol. Biosci. 13 2013 1150 1162
21. M. Li, W. Song, Z. Tang, S. Lv, L. Lin, H. Sun, Q. Li, Y. Yang, H. Hong, and X. Chen Nanoscaled poly(l-glutamic acid)/doxorubicin-amphiphile complex as ph-responsive drug delivery system for effective treatment of nonsmall cell lung cancer Acs. Appl. Mater. Inter. 5 2013 1781 1792
22. Y. Li, K. Xiao, W. Zhu, W. Deng, and K.S. Lam Stimuli-responsive cross-linked micelles for on-demand drug delivery against cancers Adv. Drug Deliv. Rev. 66 2014 58 73
23. J. Liu, P. Kopečková, H. Pan, M. Sima, P. Bühler, P. Wolf, U. Elsässer-Beile, and J. Kopeček Prostate-cancer-targeted n-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates Macromol. Biosci. 12 2012 412 422
24. S. Lv, M. Li, Z. Tang, W. Song, H. Sun, H. Liu, and X. Chen Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy Acta Biomater. 9 2013 9330 9342
25. Y. Matsumura Poly (amino acid) micelle nanocarriers in preclinical and clinical studies Adv. Drug Deliv. Rev. 60 2008 899 914
26. C.R. Miller, B. Bondurant, S.D. McLean, K.A. McGovern, and D.F. O'Brien Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes Biochemistry 37 1998 12875 12883 (Pubitemid 28433520)
27. H. Pan, M. Sima, J. Yang, and J. Kopeček Synthesis of long-circulating, backbone degradable hpma copolymer-doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy Macromol. Biosci. 13 2013 155 160
28. J.H. Park, S. Lee, J.-H. Kim, K. Park, K. Kim, and I.C. Kwon Polymeric nanomedicine for cancer therapy Prog. Polym. Sci. 33 2008 113 137 (Pubitemid 350278530)
29. L.H. Reddy, and D. Bazile Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics Adv. Drug Deliv. Rev. 2013
30. E.K. Rowinsky, E.A. Eisenhauer, V. Chaudhry, S.G. Arbuck, and R.C. Donehower Clinical toxicities encountered with paclitaxel (Taxol) Semin. Oncol. 20 1993 1 15 (Pubitemid 23239390)
31. S.A. Shaffer, C. Baker-Lee, J. Kennedy, M.S. Lai, P. de Vries, K. Buhler, and J.W. Singer In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases Cancer Chemoth. Pharm. 59 2007 537 548 (Pubitemid 46122332)
32. J. Shen, G. Song, M. An, X. Li, N. Wu, K. Ruan, J. Hu, and R. Hu The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy Biomaterials 35 2014 316 326
33. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics CA: Cancer J. Clin. 63 2013 11 30
34. J.W. Singer, B. Baker, P. De Vries, A. Kumar, S. Shaffer, E. Vawter, M. Bolton, and P. Garzone Poly-(l)-glutamic acid-paclitaxel (CT-2103) [XYOTAX (TM)], a biodegradable polymeric drug conjugate - characterization, preclinical pharmacology, and preliminary clinical data Adv. Exp. Med. Biol. 519 2003 81 99 (Pubitemid 36577702)
35. W. Song, M. Li, Z. Tang, Q. Li, Y. Yang, H. Liu, T. Duan, H. Hong, and X. Chen Methoxypoly(ethylene glycol)-block-poly(l-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers Macromol. Biosci. 12 2012 1514 1523
36. W. Song, Z. Tang, M. Li, S. Lv, H. Sun, M. Deng, H. Liu, and X. Chen Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects Acta Biomater. 10 2014 1392 1402
37. W. Song, Z. Tang, M. Li, S. Lv, H. Yu, L. Ma, X. Zhuang, Y. Huang, and X. Chen Tunable ph-sensitive poly(β-amino ester)s synthesized from primary amines and diacrylates for intracellular drug delivery Macromol. Biosci. 12 2012 1375 1383
38. W.T. Song, M.Q. Li, Z.H. Tang, Q.S. Li, Y. Yang, H.Y. Liu, T.C. Duan, H. Hong, and X.S. Chen Methoxypoly(ethylene glycol)-block-poly(l-glutamic acid)-loaded cisplatin and a combination with iRGD for the treatment of non-small-cell lung cancers Macromol. Biosci. 12 2012 1514 1523
39. M.D. Wang, D.M. Shin, J.W. Simons, and S. Nie Nanotechnology for targeted cancer therapy Expert Rev. Anticancer Ther. 7 2007 833 837 (Pubitemid 47007989)
40. R.B. Weiss The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 19 1992 670 686 (Pubitemid 23004844)
41. B. Xiang, D.-W. Dong, N.-Q. Shi, W. Gao, Z.-Z. Yang, Y. Cui, D.-Y. Cao, and X.-R. Qi PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer Biomaterials 34 2013 6976 6991
42. H.H. Xiao, W.L. Li, R.G. Qi, L.S. Yan, R. Wang, S. Liu, Y.H. Zheng, Z.G. Xie, Y.B. Huang, and X.B. Jing Co-delivery of daunomycin and oxaliplatin by biodegradable polymers for safer and more efficacious combination therapy J. Control Release 163 2012 304 314
43. K. Xiao, Y.P. Li, J.T. Luo, J.S. Lee, W.W. Xiao, A.M. Gonik, R.G. Agarwal, and K.S. Lam The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles Biomaterials 32 2011 3435 3446
44. J.P. Xu, W.D. Chen, J. Ji, and J.C. Shen Novel biomimetic polymeric micelles for drug delivery Chem. J. Chin. U 28 2007 394 396 (Pubitemid 46637560)
45. Z. Zhang, L. Mei, and S.-S. Feng Paclitaxel drug delivery systems Expert Opin. Drug Deliv. 10 2013 325 340
46. Y. Zhong, W. Yang, H. Sun, R. Cheng, F. Meng, C. Deng, and Z. Zhong Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells Biomacromolecules 14 2013 3723 3730